Axsome Therapeutics ( AXSM 2.09% ) has been a zero-to-hero biotech stock. Over the past three years, its shares rose by as much as 3,600%, but have lost nearly half of their value from their January 2020 peak. It's still a company with a lot of potential, though -- it has four leading treatment candidates in its pipeline, all with high chances of earning regulatory approval. So it's a bit peculiar that investors are shrugging the company off as if all is coming to an end.